CN Patent

CN113166761B — 用于抑制pnpla3表达的rnai构建体

Assigned to Amgen Inc · Expires 2025-09-09 · 1y expired

What this patent protects

本发明涉及用于降低PNPLA3基因表达的RNAi构建体。还描述了使用此类RNAi构建体治疗或预防肝病、非酒精性脂肪性肝病(NAFLD)的方法。

USPTO Abstract

本发明涉及用于降低PNPLA3基因表达的RNAi构建体。还描述了使用此类RNAi构建体治疗或预防肝病、非酒精性脂肪性肝病(NAFLD)的方法。

Drugs covered by this patent

givosiran-sodium (GIVOSIRAN SODIUM)

Patent Metadata

Patent number: CN113166761B
Jurisdiction: CN
Classification: —
Expires: 2025-09-09
Drug substance claim: No
Drug product claim: No
Assignee: Amgen Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.